SCHEMBL22096027

SCHEMBL22096027

COC(=O)c1nsnc1NCn1cnnn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 2/20 0.66
KDM4E B2RXH2 5/20 0.43
LMNA P02545 3/20 0.43
TP53 P04637 5/20 0.41
ALDH1A1 P00352 4/20 0.39
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.37
HSD17B10 Q99714 3/20 0.35
GAA P10253 1/20 0.35
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
POLB P06746 1/20 0.33
ALOX12 P18054 1/20 0.33
RECQL P46063 1/20 0.33
HBB P68871 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALOX15 P16050 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096015 0.80 STAT5B (1.00) STAT5BKDM4ELMNATP53ALDH1A1
SCHEMBL23615871 0.70 KDM4E (0.39) STAT5BKDM4ELMNAALDH1A1HPGD
SCHEMBL22096028 0.68 STAT5B (0.80) STAT5BKDM4ELMNATP53ALDH1A1
SCHEMBL20048201 0.68 KDM4E (0.40) STAT5BKDM4ELMNAALDH1A1HPGD
SCHEMBL22096018 0.67 STAT5B (0.75) STAT5BLMNAALDH1A1HPGDGAA
SCHEMBL11888589 0.67 STAT5B (1.00) STAT5BTP53ALDH1A1MAPTGAA
SCHEMBL14582767 0.66 NPSR1 (0.59) KDM4ELMNAALDH1A1HPGDMAPT
SCHEMBL22096009 0.66 STAT5B (0.73) STAT5BLMNATP53ALDH1A1MAPT
SCHEMBL20041699 0.65 STAT5B (0.70) STAT5BLMNATP53ALDH1A1MAPT
SCHEMBL16347649 0.63 TP53 (0.61) STAT5BLMNATP53ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885KDM4E 1626/4885LMNA 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.